ライフサイエンスコーパス: chronic myeloid leukaemia

1 newly diagnosed patients with chronic-phase chronic myeloid leukaemia.

2 ase is elevated in several cancers including chronic myeloid leukaemia.

3 eatment for patients in the chronic phase of chronic myeloid leukaemia.

4 atinib in previously untreated patients with chronic myeloid leukaemia.

5 BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukaemia and 30-50% of cases of adult a

6 was demonstrated in acute myeloid leukaemia, chronic myeloid leukaemia and acute lymphoid leukaemia,

7 hosphatase activity of PP2A is suppressed in chronic myeloid leukaemia and other malignancies charact

8 To revise the current goals of therapy of chronic myeloid leukaemia and to incorporate the influen

9 Further, in blast crisis chronic myeloid leukaemia, and a subset of acute myeloid

10 tment options, side-effects, and outcomes of chronic myeloid leukaemia, and discusses the possibility

11 B- and mantle-cell lymphomas, chronic myeloid leukaemia, and multiple myeloma, however

12 incorporate the influence of the underlying chronic myeloid leukaemia biology on directing therapeut

13 For this study the well characterised chronic myeloid leukaemia cell line KYO-1 was selected a

14 adult patients with acute myeloid leukaemia, chronic myeloid leukaemia, chronic myelomonocytic leukae

15 Chronic myeloid leukaemia (CML) arises after transformat

16 In chronic myeloid leukaemia (CML) expression of the chimer

17 The prognosis of chronic myeloid leukaemia (CML) has improved remarkably

18 y diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic phase after a

19 ntly activated and functionally required for chronic myeloid leukaemia (CML) in humans and in mouse m

20 Chronic myeloid leukaemia (CML) is a clonal disorder of

21 Chronic myeloid leukaemia (CML) is a myeloproliferative

22 Chronic myeloid leukaemia (CML) is characterized by the

23 Chronic myeloid leukaemia (CML) is driven by the activit

24 Chronic Myeloid Leukaemia (CML) is initiated and maintai

25 Chronic myeloid leukaemia (CML) is quintessential to thi

26 has provided a curative treatment option for chronic myeloid leukaemia (CML) over the past 20-30 year

27 he ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for mo

28 Chronic myeloid leukaemia (CML), a hematopoietic stem ce

29 The clonogenic cells of chronic myeloid leukaemia (CML), unlike normal haemopoie

30 topical issues in the clinical management of chronic myeloid leukaemia (CML).

31 TKIs) to eradicate LSC in chronic phase (CP) chronic myeloid leukaemia (CML).

32 b treatment of newly diagnosed chronic-phase chronic myeloid leukaemia compared with imatinib could n

33 Therapeutic advances in chronic myeloid leukaemia continue to circumvent the cha

34 Chronic myeloid leukaemia continues to instruct us in th

35 rosine-kinase inhibitors, most patients with chronic myeloid leukaemia could enjoy a near normal life

36 The management of chronic myeloid leukaemia has been revolutionized by tar

37 In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of a fat

38 inase inhibitors (TKIs) for the treatment of chronic myeloid leukaemia has changed patient outcome an

39 rs improve overall survival in patients with chronic myeloid leukaemia in chronic phase (CML-CP).

40 are available for treatment of patients with chronic myeloid leukaemia in chronic phase (CML-CP).

41 older with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase and Eastern C

42 pen-label, randomised trial in patients with chronic myeloid leukaemia in chronic phase with suboptim

43 Optimal management of patients with chronic myeloid leukaemia in chronic phase with suboptim

44 e recruited patients (aged >/=18 years) with chronic myeloid leukaemia in first chronic phase who had

45 Chronic myeloid leukaemia is a haemopoietic stem cell di

46 Chronic myeloid leukaemia is a paradigmatic haematopoiet

47 n this study, we used the p53 negative human chronic myeloid leukaemia K562 cell line.

48 Treatment of a T315I chronic myeloid leukaemia patient with axitinib resulted

49 reatment in the treatment of newly diagnosed chronic myeloid leukaemia suggest that this first-genera

50 Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available

51 six with myelodysplastic syndrome, five with chronic myeloid leukaemia (two with chronic-phase and th

52 hibitor imatinib is used in the treatment of chronic myeloid leukaemia, where it targets the intracel

53 ) therapy is feasible for some patients with chronic myeloid leukaemia with deep molecular responses;